Copyright
©The Author(s) 2023.
World J Methodol. Sep 20, 2023; 13(4): 296-322
Published online Sep 20, 2023. doi: 10.5662/wjm.v13.i4.296
Published online Sep 20, 2023. doi: 10.5662/wjm.v13.i4.296
Table 1 Baseline features in 540 patients with post-COVID-19 cholangiopathy, n (%)
Variable | Patients, n = 540 (100) |
Sex | |
Male | 69 (12.7) |
Female | 26 (4.8) |
Age > 50 year | 66 (12.2) |
Liver enzymes | |
High (> 45) | 507 (93.8) |
Total bilirubin | |
High (> 1.2 mg/dL) | 343 (63.5) |
Alkaline phosphatase | |
High (> 147 IU/L) | 488 (90.3) |
Ultrasound findings | |
Biliary ductal dilatation with fibrosis | 225 (41.6) |
MRI Findings | |
Bile duct thickening and enhancement | 258 (47.7) |
Beading of intrahepatic ducts | 247 (45.7) |
Peribiliary diffusion | 155 (28.7) |
Histopathology with secondary sclerosing cholangitis | 402 (74.4) |
Orthotopic liver transplantation | 16 (2.96) |
Table 2 Summary of systemically reviewed clinical cases
Ref. | Age, yr | Sex | Clinical presentation | Elevated liver enzyme | U/S findings | MRI findings | Respiratory failure | Renal failure | Histopathology | OLT | Outcome |
Roth et al[28], 2021 | 38 | Male | Post-COVID-19 cholangiopathy | Yes | Intrahepatic bile ducts beading, with sub-segmental strictures and dilatation | Beading of intrahepatic ducts | Yes, required MV; On supplemental oxygen, then off on day 63 and decannulated | Yes, recovered | Portal tract findings; Mild duct paucity, moderate bile duct swelling & reaction; Mild portal tract inflammation; Endothelial hepatic artery swelling; Portal veins with focal endo phlebitis | Not done | Recovered |
25 | Male | Post-COVID-19 cholangiopathy | Yes | Hepatomegaly, extrahepatic bile duct dilatation, intrahepatic bile duct dilatation | Beading of intrahepatic ducts | Yes, required MV; On supplemental oxygen, then off on day 112 and decannulated | Yes, recovered | Portal tract findings; Moderate duct paucity, moderate bile duct swelling & reaction. Moderate portal tract inflammation; Endothelial hepatic artery swelling; Portal veins with focal endo phlebitis | Not done | Recovered | |
40 | Female | Post-COVID-19 cholangiopathy | Yes | Hepatomegaly, no dilatation | Peribiliary diffusion, moderate portal and periportal fibrosis | Yes, remains with tracheostomy & MV, and then off MV on day 63 | Yes, recovered | Portal tract findings; Moderate duct paucity, moderate bile duct swelling & reaction; Severe portal tract inflammation; Endothelial hepatic artery swelling; Portal veins with focal endo phlebitis | Not done | Death, cardiac arrest | |
Faruqui et al[13], 2021 | Mean age 58 | Male | Post-COVID-19 cholangiopathy | Yes | U/S showed; extrahepatic bile duct dilatation and intrahepatic bile duct dilatation and periportal diffusion | MRI showed, beading of intrahepatic ducts (11/12, 92%); Peribiliary diffusion (10/12, 83%); Bile duct wall thickening (7/12, 58%) | Patients required MV | Yes, recovered | Large duct obstruction without clear bile duct loss | Done OLT | Had t successful recovery and rapid clinical improvement |
Mean age 58 | Female | Post-COVID-19 cholangiopathy | Yes | Experiencing persistent jaundice, hepatic insufficiency, and/or recurrent bacterial cholangitis | Beading of intrahepatic ducts; Peribiliary diffusion; Bile duct wall thickening | Patients required MV | Yes, recovered | Large duct obstruction without clear bile duct loss | Highly recommended for OLT. Patient on transplantation waiting list, still not done OLT at time of study | Recovery with long-term liability and comorbidity | |
Mean age 58 | Male | Post-COVID-19 cholangiopathy | Yes | Experiencing persistent jaundice, hepatic insufficiency, and/or recurrent bacterial cholangitis | Beading of intrahepatic ducts; Peribiliary diffusion; Bile duct wall thickening | Patients required MV | Yes, recovered | Large duct obstruction without clear bile duct loss | Highly recommended for OLT. Patient on transplantation waiting list, still not done OLT at time of study | Recovery with long-term liability and comorbidity | |
Mean age 58 | Male | Post-COVID-19 cholangiopathy | Yes | Experiencing persistent jaundice, hepatic insufficiency, and/or recurrent bacterial cholangitis | Beading of intrahepatic ducts; Peribiliary diffusion; Bile duct wall thickening | Patients required MV | Yes, recovered | Large duct obstruction without clear bile duct loss | Highly recommended for OLT. Patient on transplantation waiting list, still not done OLT at time of study | Recovery with long-term liability and comorbidity | |
Mean age 58 | Male | Post-COVID-19 cholangiopathy | Yes | Experiencing persistent jaundice, hepatic insufficiency, and/or recurrent bacterial cholangitis | Beading of intrahepatic ducts; Peribiliary diffusion; Bile duct wall thickening | Patients required MV | Yes, recovered | Secondary sclerosing cholangitis | Highly recommended for OLT, patient on transplantation waiting list, still not done OLT at time of study | Recovery with long-term liability and comorbidity | |
Mean age 58 | Male | Post-COVID-19 cholangiopathy | Yes | Intrahepatic bile duct dilatation and periportal diffusion | Beading of intrahepatic ducts; Peribiliary diffusion; Bile duct wall thickening | Patients required MV | Yes, recovered | Secondary sclerosing cholangitis | OLT Not done | Recovery with long-term liability and comorbidity | |
Mean age 58 | Male | Post-COVID-19 cholangiopathy | Yes | Intrahepatic bile duct dilatation and periportal diffusion | Beading of intrahepatic ducts; Peribiliary diffusion; Bile duct wall thickening | Patients required MV | Yes, recovered | Secondary sclerosing cholangitis | OLT Not done | Recovery with long-term liability and comorbidity | |
Mean age 58 | Male | Post-COVID-19 cholangiopathy | Yes | Intrahepatic bile duct dilatation and periportal diffusion | Beading of intrahepatic ducts; Peribiliary diffusion | Patients required MV | Yes, recovered | Secondary sclerosing cholangitis | OLT Not done | Recovery with long-term liability and comorbidity | |
Mean age 58 | Male | Post-COVID-19 cholangiopathy | Yes | Intrahepatic bile duct dilatation and periportal diffusion | Beading of intrahepatic ducts; Peribiliary diffusion | Patients required MV | Yes, recovered | Secondary sclerosing cholangitis | OLT Not done | Recovery with long-term liability and comorbidity | |
Mean age 58 | Male | Post-COVID-19 cholangiopathy | Yes | Intrahepatic bile duct dilatation and periportal diffusion | Beading of intrahepatic ducts; Peribiliary diffusion | Patients required MV | Yes, recovered | Secondary sclerosing cholangitis | OLT Not done | Recovery with long-term liability and comorbidity | |
Mean age 58 | Male | Post-COVID-19 cholangiopathy | Yes | Intrahepatic bile duct dilatation and periportal diffusion | Beading of intrahepatic ducts | Patients required MV | Yes, recovered | Secondary sclerosing cholangitis | OLT Not done | Recovery with long-term liability and comorbidity | |
Mean age 58 | Male | Post-COVID-19 cholangiopathy | Yes | Intrahepatic bile duct dilatation and periportal diffusion | MRI not available | Patients required MV | Yes, recovered | Secondary sclerosing cholangitis | OLT Not done | Recovery with long-term liability and comorbidity | |
Li et al[29], 2022 | N/A | Two sample mendelian randomization | The autoimmune diseases showed not associated with COVID-19 infection | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Hunyady et al[30], 2023 | N/A | 24 Patients | Post-COVID-19 cholangiopathy developed after a median of 91 d | Yes | N/A | N/A | Patients required MV, the median was 48 d among all patients | N/A | COVID-SSC and CIP-SSC share the same clinical phenotype | N/A | UDCA showed great improvement in patients without liver cirrhosis and reduced severity in patients with liver cirrhosis, while OLT showed significant improvement in patient with liver cirrhosis |
Weaver et al[31], 2021 | 63 | Male | Post-COVID-19 cholangiopathy | Yes | Sludge in the gallbladder, no biliary ductal dilation, and patent vasculature | N/A | Patients required MV | N/A | Filling defects in the common bile duct as well as an irregular and beaded appearance of the intrahepatic ducts | Not done | Recovered, after ERCP sphincterotomy followed by balloon sweep of the biliary ducts and removal of thick stone |
Hartl et al[32], 2022 | N/A | N/A | Post-COVID-19 cholangiopathy (65 patients with CLD of 496 patients included in the study, around 24.6% non-ACLD vs ACLD 10.6% associated with COVID | Yes. Alkaline phosphatase showed (pre: 91.0 vs T1: 121.0 vs last: 175.0 U/L) and gamma glutamyl transferase GGT (pre: 95.0 vs T1: 135.0 vs last: 202.0 U/L) | N/A | N/A | N/A | N/A | 20% of patients with CLD developed progressive cholestasis post-COVID-19 cholangiopathy, and patients with NASH/NAFLD also have a risk of developing cholestatic liver failure and secondary sclerosing cholangitis post-COVID-19 | N/A | N/A |
Duengelhoef et al[33], 2022 | N/A | N/A | Post-COVID-19 cholangiopathy, associated more with Autoimmune hepatitis AIH as well as post COVID vaccine than PBC and PSC patients | Yes | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
John et al[34], 2023 | N/A | N/A | Post-COVID -19 cholangiopathy study included 1607 patients with liver cirrhosis used UDCA | Yes | N/A | N/A | N/A | N/A | N/A | N/A | UDCA showed great improvement in patients with liver cirrhosis, by decreased symptoms and decreased COVID-19 infection |
Heucke et al[35], 2022 | N/A | 48 | Post-COVID-19 cholangiopathy 13% from 496 patients developed CLD; 23% of patients with CLD developed cholestasis/cholangiopathy | Yes (ALT & AST were elevated in 50 patients less than 5 times upper limit of normal. While in late-stage alkaline phosphatase and GGT were highly progressively elevated | N/A | N/A | Yes, require oxygen supply & some patients MV | Yes, some patients required dialysis for renal failure | The histopathology reported SARS-CoV-2 RNA and/or proteins in human liver tissue and bile samples, this SARS-CoV-2 RNA may lead to provoke a strong proinflammatory cytokine response (TNF, IL‐1, IL‐6) with hypercoagulation, endothelial damage, consecutive venous and arterial embolism, as well as secondary parenchymal damage | 9 patients listed for OLT and 6 patients done OLT with good recovery | 16 patients died, and 24 patients were treated with ketamine during the acute phase of COVID-19 and around 28 patients with SSC from 48 were reduced after using UDCA treatment |
Bazerbachi et al[36], 2022 | 56 | Female | Post-COVID-19 cholangiopathy | Yes alkaline phosphatase 1574U/L, total bilirubin 11 mg/dL, ALT 88 U/L, AST 101 U/L | EUS showed a left hepatic duct stricture and heterogenous, non-shadowing cylindric objects in the main bile duct | N/A | Yes, require tracheostomy & MV | Yes, developed renal failure and required hemodialysis | LHD stricture with upstream dilation of the left ducts, and obliteration of right intrahepatic with secondary sclerosing changes | Not done | Improved, casts were swept and removed, and left lobe was stented with a 10 Fr 20 cm plastic stent improving bilirubin level to a baseline of 3 mg/dL |
Cho et al[37], 2022 | 47 | Female | Post-COVID-19 cholangiopathy | Yes, highly elevated ALP-positive ANA, anti-mitochondrial highly positive | N/A | N/A | N/A | N/A | N/A | N/A | Post-COVID-19 cholangiopathy may be due to direct cytotoxicity from SARS-CoV-2 active replication, hypoxia induced respiratory failure, drug induced liver injury, vascular coagulopathy, immune mediated liver damage |
57 | Male | Post-COVID-19 cholangiopathy | Yes, hypogammaglobinemia, high GGT, elevated AST/ALT, positive anti-mitochondrial antibody, anti-smooth muscle antibodies, and anti-double stranded DNA antibodies | N/A | N/A | N/A | N/A | N/A | OLT Considered for some patients | ||
N/A | N/A | Post-COVID-19 cholangiopathy | Yes, ALP > three times | N/A | MRCP showed dilatation of hepatic ducts with stenosis and beading of intrahepatic ducts | N/A | N/A | N/A | |||
N/A | 24 Patients | Post COVID-19 Cholangiopathy | Yes | N/A | N/A | N/A | N/A | N/A | |||
Yu et al[38], 2022 | N/A | N/A | Post-COVID-19 cholangiopathy | Yes | N/A | N/A | N/A | N/A | N/A | N/A | The patients are not only related to liver disease, but also cholangitis may be due to viral cholangitis, systemic inflammation response, and hypoxic liver injury |
Sanders et al[39], 2021 | 57 | Male | Post-COVID-19 cholangiopathy | Yes | Dilated CBD with a distal CBD stone | N/A | Yes, required MV. (Tracheostomy & gastrostomy) | Renal impairment required fluid resuscitation | N/A | N/A | Improved, biliary cast removed by ERCP, and bile duct stent and patient referred for cholecystectomy |
López Romero-Salazar et al[40], 2022 | 76 | Male | Post-COVID-19 cholangiopathy | Yes, elevated ALT & AST developed AIH and complicated to liver cirrhosis secondary to primary biliary cholangitis (PBC) igg positive, ANA | U/S showed hepatic fibrotic inflammation, dilated lobes, and biliary ducts | N/A | N/A | N/A | Biopsy showed lobular hepatitis, with intense interface, centrilobular necrosis with lymphoplasmacytic inflammation | N/A | The patient has poor prognosis due to liver cirrhosis, the study emphasizes the hypothesis that AIH induced due to or post COVID-19 vaccination. Patient given UDCA and obeticholic acid |
Wall et al[41], 2022 | N/A | N/A | Post-COVID-19 cholangiopathy | Yes | N/A | N/A | N/A | N/A | N/A | N/A | The study showed to avoid using SARS-CoV-2-positive donors for liver transplantation unless there is a justifying indicator such as recipient illness severity |
Ghafoor et al[42], 2022 | Mean Age 60.5 | 15 Male patients | Post-COVID-19 cholangiopathy | Yes | N/A | All patients had intrahepatic bile duct strictures and 10 patients had associated upstream dilatation. Fourteen patients showed intrahepatic bile duct beading. One patient had extrahepatic bile duct structuring; 9 patients showed high signal on T2 and diffusion weighted images & 7 patients showed patchy arterial phase hyperenhancement; 2 patients showed biliary casts. Vascular complication, and periportal lymphadenopathy were not seen on MRI/MRCP | N/A | N/A | N/A | N/A | The post-COVID-19 cholangiopathy patients showed on MRI/MRCP multiple intrahepatic bile duct strictures with intrahepatic bile duct beading |
Singh et al[43], 2021 | 57 | Male | Post-COVID-19 cholangiopathy | Yes, elevated ALT, AST, GGT, hypergammaglobulinemia and anti-mitochondrial antibody, anti-smooth muscle antibody and anti-double stranded DNA antibodies | N/A | N/A | N/A | N/A | N/A | N/A | The patient diagnosed with auto immune hepatitis with primary biliary cholangitis overlap syndrome triggered by COVID-19 |
Seifert et al[44], 2023 | N/A | 7 patients (3 males & 4 females) | Post-COVID-19 cholangiopathy among 7 patients of 544 patients with cholangitis. 4 patients had SSC due to other reasons | Yes, elevated GGT, Alkaline phosphatase ALP among 7 patients more than 4 patients non COVID-19 | N/A | N/A | N/A | N/A | N/A | N/A | The 7 patients with post-COVID-19 cholangiopathy showed more hepatitis and cholangitis than other group non-COVID cholangitis most probably due to direct cytopathologic effect of COVID virus |
Lee et al[45], 2021 | 64 | Male | Post-COVID-19 cholangiopathy | Yes | U/S intrahepatic bile ducts loss | MRI not available | Required MV | Yes, Recovered | Diffuse hepatic injury, onion skinning of the bile ducts and bile duct loss in scattered portal tracts | OLT not done; patient need to be stable for the operation | Not recovered |
Cunha-Silva et al[46], 2023 | 45 | Male | Post-COVID-19 cholangiopathy | Yes, elevated in the first 2-wk AST, ALT, GGT, Alkaline phosphatase post SARS-CoV-2 infection: ANA and anti-smooth muscle-positive. Negative viral hepatitis & anti-mitochondrial antibodies | N/A | No dilatation of biliary ducts | N/A | AKI after recovering 2 wk from COVID-19 | Numerous foci of lobular necrosis but with no ductopenia or portal biliary reaction. After 2 mo: Biopsy showed: extensive areas of confluent necrosis, hepatocytes regenerating into pseudorosettes and numerous plasma cells, non-suppurative cholangitis all these features diagnosed by PARIS Criteria as AIH-PBC-OS | N/A | The patient is given prednisolone in the first phase, then after 2 mo added azathioprine and UDCA to management and showed great response and recovery |
Hamid et al[47], 2021 | N/A | N/A | Post-COVID-19 cholangiopathy | Yes, elevated AST, ALT, low albumin, and low platelet | N/A | N/A | N/A | N/A | Endoscopy and ERCP are recommended by WGO | N/A | OLT is advised to be postposed till SARS-CoV-2 infection treated and patient recovered |
Kroepfl et al[48] | N/A | 2 patients | Post-COVID-19; cholangiopathy | Yes | N/A | N/A | N/A | N/A | ERCP biopsy showed severely destructed biliary mucosa with ischemia and epithelial roughness | N/A | N/A, early cholangioscopy can confirm the diagnosis |
Mayorquín-Aguilar et al[24] | 3 Cases | Post-COVID-19 cholangiopathy | Yes | Not available | Mild intrahepatic; Biliary ductal; Dilatation with; Multifocal strictures or; Beading without; Extrahepatic biliary; Dilatation | Yes, required MV | Yes, recovered | SSC-CIP beading of intrahepatic ducts, bile duct wall thickening with enhancement, and peribiliary diffusion high signal | 2 Done OLT, 1 Not done | 2 males death; 1 female recovered | |
45 | Male | ||||||||||
52 | Male | ||||||||||
46 | Female | ||||||||||
Graciolli et al[49] | 63 | Male | Post-COVID-19 cholangiopathy | Yes | Not available | Dilations with intercalated stenotic segments in intra and extrahepatic bile ducts and edema of the bile ducts corresponding to inflammation of the adjacent parenchyma | Yes | Not available | Intrahepatocellular cholestasis | Not done | Death, infected ulcer, palliative care |
Keta-Cov research group[50] | Median Age 59 (35-65) | Male | Post-COVID-19 cholangiopathy | Yes, elevated AST, ALTGGT, ALP, total bilirubin all elevated | N/A | Aspects of sclerosing cholangitis, with strictures and dilatations of intrahepatic bile ducts, peribiliary cysts and multiple biliary casts | All patients required M/V | All patients developed acute kidney injury required renal replacement therapy | ERCP showed filling defects in the common bile duct and rarefication of the intrahepatic biliary tract and biopsy showed biliary obstructions, including cholangiolar proliferation, biliary plugs, portal inflammation with neutrophil infiltrates, extensive biliary fibrosis and cirrhosis | N/A | Intravenous ketamine is dose dependant and used for maintenance sedation of patients required M/V for acute respiratory distress syndrome ARDS, and showed associated with biliary obstructions, cholestatic liver injury, biliary cirrhosis, and end-stage liver disease, that’s the reason the new guidelines is not recommend ketamine especially if prolonged or at higher dose |
Male | |||||||||||
Male | |||||||||||
Female | |||||||||||
Female | |||||||||||
Zdanowicz et al[51], 2022 | Paediatric patient | Male | Post-COVID-19 cholangiopathy | Yes | N/A | N/A | N/A | N/A | N/A | N/A | Patient developed autoimmune hepatobiliary diseases, autoimmune sclerosing cholangitis ASC which required long-term liver function monitoring |
Schwarz et al[52], 2022 | N/A | 15 patients | Post-COVID-19 cholangiopathy | Yes, GGT is elevated in 15 patients with SSC-CIP after lung transplantation out of 40 patients in the study. ALP is elevated after lung transplant | N/A | N/A | 15 patients out of 40 developed SSC-CIP underwent lung transplant | N/A | N/A | N/A | GGT showed to be a sensitive parameter to predict severity in SSC-CIP |
Keskin et al[53], 2022 | N/A | 32 patients | Post-COVID-19 cholangiopathy | Yes | N/A | N/A | N/A | N/A | N/A | N/A | Technical problems with ECRP were more common in biliary patients with delay group than in those without delay, while 7 pancreatic patients showed no difference in ERCP with or without delay of intervention. Technical issues considered such as abundant stone sludge in bile duct, stent migration, etc |
Bartoli et al[54], 2021 | 44 | Female | Post-COVID-19 cholangiopathy | Yes, AST, ALT elevated and GGT, ALP elevated more ANA positive, anti-mitochondrial-positive, anti-smooth muscle negative | U/S showed slightly enlarged liver with moderate steatosis and a mildly enlarged spleen | N/A | Yes, required intubation and MV | N/A | Florid ductal lesions, moderate peri-portal fibrosis, portal chronic inflammatory infiltrate | Not done | Patient treated with UDCA and discharged and breathing normally, also treated from Guillain barre syndrome GBS by intravenous immunoglobulin |
Ferreira et al[55], 2022 | N/A | 4 cases | Post-COVID-19 cholangiopathy | Yes | N/A | N/A | N/A | N/A | ERCP showed beaded appearance of intrahepatic bile ducts and bile casts | N/A | One patient undergone stone removal, and one patient complicate with liver cirrhosis, the other two progressed to advanced chronic liver disease |
Bütikofer et al[56], 2021 | N/A | 20 Cases | Post-COVID-19 cholangiopathy | Yes 9 patients with severe cholestasis 11 patients with mild cholestasis | N/A | N/A | N/A | N/A | Ischemic changes to the perihilar bile ducts | N/A | SSC is more common and severe in critically COVID-19 patients, with prolonged ICU period |
Zafar et al[57], 2022 | N/A | 2 Cases | Post-COVID-19 cholangiopathy | Yes | N/A | N/A | N/A | N/A | N/A | N/A | Both patients developed SSC post-COVID-19 vaccination, which lead to hepatitis and eventually cholangitis |
Otani et al[58], 2022 | N/A | N/A | Post-COVID-19 cholangiopathy in some cases of 166 cases | Yes | N/A | N/A | N/A | N/A | N/A | N/A | 166 cases for endoscopic procedures for causes; Cholangitis, GI bleeding, Obstructive jaundice, neoplasia, COVID-19 led to delay in endoscopic procedures which led to delayed diagnosis of cholangitis, cancers, etc. |
Cesar Machado et al[59], 2022 | 66 | Male | Post-COVID-19 cholangiopathy | Yes | Ultrasound showed slight hepatomegaly and no bile duct dilatation | MRI showed biliary cast, also revealed. Diffuse irregularity of intra- and extrahepatic bile ducts, with multiple focal strictures alternating with mild focal dilations of the biliary tree, suggesting a sclerosing cholangiopathy | Yes, required MV | Yes, required haemodialysis | Biopsy showed a prominent bile ductular reaction, cholangiocyte injury, inflammatory infiltrate rich in neutrophils, biliary infarctions, marked cholestasis, and portal fibrosis | Not done OLT, due to poor clinical condition | Slight recovery, under observation & follow-up |
Steiner et al[60], 2022 | 33 | Female | Post-COVID-19 cholangiopathy | Yes, elevated liver enzymes AST, ALT, marked elevated GGT, ALP | N/A | MRCP done showed cholangiopathy | Yes hypoxia required intubation and MV, patient developed respiratory distress syndrome in which she was given veno-venous extracorporeal membrane oxygenation | Yes renal failure, and went through haemodialysis frequently | ERCP done showed cholangiopathy | OLT not done | Patient passed away, her clinical condition deteriorated, with severe hypoxia, renal failure, and multi-organ failure |
Gourjault et al[61], 2021 | 55 | Male | Post-COVID-19 cholangiopathy | Yes, elevated AST, ALT high GGT, ALP, elevated bilirubin, LDH | N/A | Periportal hypersignal without hepatic biliary dilatation | Yes, Required intubation& MV for 20 d with four sessions prone position | N/A | Interlobular biliary lesions with cholestasis | Waiting list for OLT | Discharged home, he had sphincterotomy and stone removal, planned for OLT |
45 | Male | Hepatic steatosis without hepatomegaly or biliary dilatation | Diffuse intra-hepatic dilatation and liver steatosis without any focal obstructing lesion | MV for 26 d and sedated with ketamine for 24 d then he was on ECMO for 18 d | Fifteen sessions of hemodialysis | Discharged home, improved, not done OLT | |||||
30 | Male | US normal | Progressive irregular intrahepatic ductal dilatation | MV for 12 d with ketamine sedation, then replaced by ECMO for 29 d with 6 sessions of prone position | 30 sessions of hemodialysis | Biopsy showed cholestatic hepatitis, bile ducts dystrophy | OLT done 11 mo after his admission | Developed liver failure with ascites, prolonged prothrombin, OLT done | |||
Tafreshi et al[62], 2021 | 38 | Male | Post-COVID-19 cholangiopathy | Yes, mildly elevated AST, ALT and GGT mild bilirubin level | Intrahepatic biliary ductal irregularity and a markedly thickened common bile duct | Diffuse mild intrahepatic biliary distention, marked beading and irregularity& mild irregularity of the extra hepatic common bile duct | Required intubation & MV | N/A | Biopsy showed cholestatic hepatitis with cholangiocyte injury, bile ductular proliferation, canalicular cholestasis | Waiting list for OLT | Improved by treatment, waiting list for OLT |
Leonhardt et al[63], 2023 | N/A | N/A | Post-COVID-19 cholangiopathy | Yes | N/A | N/A | Yes. Intubated on MV | N/A | N/A | N/A | One patient developed SSC-CIP in every 43 invasive ventilated COVID-19 patients (total 1082 patients) |
Zengarini et al[64], 2022 | 30 | Female | Post-COVID-19 cholangiopathy | Yes | N/A | N/A | N/A | N/A | N/A | N/A | Patient developed subacute cutaneous lupus erythematosus post COVID-19 vaccination in patient with PBC |
Wendel-Garcia et al[65], 2022 | N/A | N/A | Post-COVID-19 cholangiopathy | Yes. High total bilirubin | N/A | N/A | N/A | N/A | N/A | N/A | The study showed 243 patients; 170 Patients infused with ketamine developed post-COVID-19 cholangiopathy while other patients received propofol, fentanyl were not associated with cholestatic liver injury |
Morão et al[66], 2022 | 46 | Female | Post-COVID-19 cholangiopathy | Yes | N/A | MRCP; liver abscesses, intrahepatic bile duct dilation with multiple strictures and some linear repletion defects at the bifurcation of the common hepatic duct | Intubation with MV 12 d | N/A | ERCP Showed; biliary casts | N/A | N/A |
Lee et al[67], 2022 | 56 | Female | Post-COVID-19 cholangiopathy | Yes, hepatitis C, AST, 243, ALT 630, ALP 449, GGT 2765 | N/A | N/A | N/A | N/A | Granulomatous cholangitis, nonsuppurative with destruction and proliferation of bile ducts with PBC Also immune infiltrations of CD3 T-cells, CD8 T-cells | N/A | Patient improved and discharged after high dose UDCA treatment, liver enzymes become normal |
Nikoupour et al[68], 2020 | 35 | Male | Post-COVID-19 cholangiopathy | Yes | N/A | N/A | N/A | N/A | N/A | OLT done before 3 yr from COVID-19 infection | Two identical twins had COVID-19 infection, both developed PSC, one of them who had OLT showed improvement with mild symptoms, while the other twin had more severe symptoms |
35 | Male | Did not have OLT | |||||||||
Arnstadt et al[69], 2021 | 62 | N/A | Post-COVID-19 cholangiopathy | Yes | Echogenic intraductal longitudinal structures characteristic for intraductal casts and for SSC-CIP | MRCP showed irregular intrahepatic bile ducts | Yes, need long-term ventilation | N/A | Necrotic bile ducts | N/A | N/A |
Meersseman et al[70], 2021 | Mean age 48-68 | Male | Post-COVID-19 cholangiopathy | Yes, elevated GGT, ALP, AST, ALT | N/A | MRCP showed focal strictures in intrahepatic bile ducts with intraluminal sludge and casts | Yes, intubated & MV then VV- ECMO | Yes, required renal support | ERCP: Patient 1 diffuse beading of the intrahepatic biliary system, patient 2 & 3 diffuse beading of the intrahepatic biliary ducts, patient 4 focal strictures on the right hepatic duct | OLT done for patient 1 and 2patient 3 & 4 did not undergo OLT | Patient 1 is doing well, patient 2 died due to septic shock and pneumonia, patient 3 have mild SSC-CIP, patient 4 died due to lethal liver hemorrhage |
Durazo et al[5], 2021 | 47 | Male | Post-COVID cholangiopathy | Yes | Cholelithiasis without evidence of acute cholecystitis | Mild intrahepatic biliary ductal dilatation with multifocal strictures and beading with intra hepatic dilatation but without extrahepatic biliary dilatation | Yes, off MV on day 29 | Yes, recovered | Liver abscess; Bile collection associated with bile duct dilatation with vacuolization and neutrophilia. Endothelial hepatic arteries swelling. Severe portal tract inflammation with Obliterative venopathy | OLT done | Recovered |
Raes et al[71], 2022 | 64 | Male | Post-COVID-19 cholangitis | Yes | N/A | N/A | Yes, MV then venovenous ECMO VV-ECMO | N/A | N/A | N/A | Passed away; patient having CAHA, progressive liver failure, secondary to ischemic cholangitis |
Fajardo et al[72], 2021 | 24 | Female | Post-COVID-19 cholangitis | Yes, GGT, ALP, AST, ALT, bilirubin | US: thickening of the gallbladder without stones | MRI: showed normal biliary tree and wall oedema of the gallbladder | N/A | N/A | Cholangitis of the small bile ducts consisting of a mixed inflammatory infiltrate with lymphocytes, plasma cells and neutrophils, accompanied by eosinophils, localized around and within the bile ducts | Not done OLT | Improved, patient discharged after laparoscopic cholecystectomy and liver biopsy |
Pizarro Vega et al[73], 2023 | 63 | Male | Post-COVID-19 cholangiopathy | Yes, GGT high in all patients especially in patient NO. 3 to 143 U/L then reached to 1130 U/L and patient 4 reached 3550 U/L. AST is high and higher in patient 4 to 82 U/L and patient 5 to 85 U/L then reached maximum 250 and 148, respectively. And patient 1 reached 1520 U/L. High tot. Bilirubin, ALT, ALP | N/A | MRI showed intrahepatic duct dilatations, stenosis without lithiasis, no extrahepatic duct alteration | Yes, required intubation, MV. Pronosupination | Yes, impaired renal function, required vasoactive drugs | No liver biopsy | One patient planned for OLT | All patients treated with UDCA and discharge. 3 patients re-admitted due to complication, patient 4 had pleural empyema. Patient 5 had cholecystectomy, patient 6 readmitted for acute cholangitis without lithiasis, no patients died during follow up |
66 | Female | ||||||||||
60 | Male | ||||||||||
65 | Male | ||||||||||
44 | Female | ||||||||||
68 | Male | ||||||||||
Knooihuizen et al[74], 2021 | 54 | Female | Post-COVID-19 cholangiopathy KISC | Yes, ALP peaked 2239 U/L, GGT 773 U/L, AST 1260 U/L, ALT 1729 U/L | N/A | MRI showed intrahepatic biliary dilatation with a beaded appearance & dilated common bile duct with distal narrowing | Yes | Yes | Liver biopsy showed minimal infiltration of neutrophils in the portal tract and lobule without cholestasis, also showed portal tract with bile duct injury | Not done | Patient have KISC during intensive sedation, then ceased the KISC is transient, patient for repeat MRCP |
Zhou et al[75], 2022 | 36 | Female | Post-COVID-19 vaccination leading autoimmune hepatitis | Yes, AST 581, ALT 588 elevated, GGT, ALP slight elevation, bilirubin 1.4 | N/A | N/A | N/A | N/A | Liver biopsy showed interface hepatitis with portal infiltration and discrete presence of rosette formation and apoptotic hepatocytes | Not done | Patients have Autoimmune hepatitis AIH post vaccination (Moderna mRNA), treatment given after 2nd dose vaccine with prednisolone PSC treated with UDCA and ERCP |
Muehlenberg et al[76], 2021 | 80 | Female | Post-COVID-19 cholangiopathy | Yes, AST 100 U/L, ALT 113 U/L, bilirubin 12 mg/dL | US of liver and bile duct were normal | N/A | Yes, intubation and MV with antibiotics and catecholamine treatment | N/A | N/A | N/A | Patient done ERCP with papillotomy and foreign body extraction |
Soldera and Salgado[77], 2021 | 62 | Male | Post-COVID-19 cholangiopathy | Yes | Not Available | Diffuse irregularity of the intrahepatic bile ducts associated with sacular dilations suspicious for cholangiolithic abscesses | Yes | Not available | Intense cytoplasmic vacuolization of cholangiocytes and microvascular alterations | OLT done | Recovery |
Rojas et al[78], 2021 | 29 | Female | Post-COVID-19 cholangiopathy | Yes | Resemble SSC (secondary sclerosing cholangitis) but no portal inflammation, dilatation, or fibrosis) | MRI is negative | Yes, off MV on day 30 | Yes, recovered | Low periportal inflammatory infiltrate without necrosis but with a severe obstructive cholestatic pattern | Not done | Not recovered |
Dhaliwal et al[23], 2022 | 42 | Female | Post-COVID-19 cholangiopathy | Yes | Not Available | Mild intrahepatic biliary ductal dilation. With subtle central biliary enhancement concerning for. Cholangitis along with hypodense material hin extrahepatic. Biliary system likely representing transiting gallbladder. Sludge | Not required MV | No | Filling defects secondary to multiple large biliary casts (Biliary case syndrome) | OLT Done | Recovery with long-term liability and comorbidity |
Caballero-Alvarado et al[79], 2023 | 7 cases | 7 cases | Post-COVID-19 cholangiopathy | Yes | Not available | Not available | Not available | Yes, recovered | Secondary sclerosing cholangitis | 1 done OLT 6 send for consideration of OLT | One recovered, 6 no data available |
Soldera et al l[26], 2023 | 50 | One male | Post-COVID-19 cholangiopathy | Yes | Not available | MRI showed intra-hepatic sclerosing cholangitis and a dilated chilidium, with no signs of lithiasis (11 mm) | Yes, required MV | Yes, required haemodialysis | ERCP which showed a cast in the format of the external biliary tract, which was removed | Not done OLT | Recovered post cast removal |
Franzini et al[80], 2022 | 65 | Male | Post-COVID-19 cholangiopathy | Yes | U/S showed no abnormalities | MRI Not available | Yes, required MV; under Fentanyl, Midazolam, and Ketamine sedation | Yes, required haemodialysis | ERCP revealed rarefaction of intrahepatic bile ducts, and removal of biliary casts | OLT Not done | No improvement |
Roda et al[81], 2022 | 63 | Male | Post-COVID-19 cholangiopathy | Yes | Ultrasound results was inconclusive | MRI not done | Yes, required MV, and veno-venous extracorporeal membrane oxygenation support (VV-ECMO). And eventually done bilateral lung transplant | Acute renal failure (AKI III); chronic illness neuropathy; several episodes of bacterial superinfections and lastly, PLS, characterized by severe haemolysis | Transjugular hepatic biopsy was performed with histopathological evidence of portal and periportal fibrosis, and intraparenchymal cholestasis with cholangiopathy and vasculopathy | OLT not done, patient did bilateral lung transplant | Not recovered, patient passed away due to Multiorgan failure MOF due to septic shock |
Tebar et al[82], 2022 | 43 | Male | Post-COVID-19 cholangiopathy | Yes | Ultrasound Not available | MRI not done | Yes, required MV | Not available | ERCP, MRCP Showed: Bile cholestatic, toxic. Cause necrosis of cholangiocytes and stenosis, determining persistent and irreversible biliary obstruction, with rapid progression to liver cirrhosis | Not available | Not available |
Santisteban Arenas et al[83], 2022 | 6 cases | Post-COVID-19 cholangiopathy | Yes | Ultrasound not available | Destruction and curling of the pathway, beading of the intrahepatic bile duct | Yes, all 6 cases required MV | 1 male not having renal failure or haemodialysis. All other 5 cases have renal failure; 2 females not required haemodialysis; 2 males required haemodialysis; 1 male have renal failure but not required haemodialysis | MRCP/ERCP showed destruction of biliary tract. In three of the six patients underwent liver biopsy, the most frequent findings were the presence of a reaction. Ductular, proliferation of cholangioles, infiltrate. Inflammatory associated with the biliary epithelium with component. Lymphoplasmocyte and polymorphonuclear neutrophils | Not available | 1 patient died, 5 other survived with severe comorbidities such as pneumonia, tracheal stenosis, pressure ulcers etc. | |
55 | Male | ||||||||||
54 | Male | ||||||||||
62 | Male | ||||||||||
56 | Female | ||||||||||
73 | Female | ||||||||||
34 | Male |
- Citation: Rasheed MA, Ballotin VR, Bigarella LG, Soldera J. Post-COVID-19 cholangiopathy: Systematic review. World J Methodol 2023; 13(4): 296-322
- URL: https://www.wjgnet.com/2222-0682/full/v13/i4/296.htm
- DOI: https://dx.doi.org/10.5662/wjm.v13.i4.296